Nov 16, 2015
LTX-315 development history presented at European peptide conference

Mette Husbyn (CMC Manager in Lytix Biopharma) presented LTX-315 at EuroPeptides in Berlin Tuesday 17th November. She gave an overview of the development of the oncolytic immunotherapeutic peptide, from the early design of numerous peptide candidates, through various mode of action studies and preclinical and clinical data.

The potential of LTX-315 as a combination partner with other immunotherapies was also discussed.

Read about EuroPeptides